- Conditions
- Metastatic Colorectal Cancer
- Interventions
- MEK162, Panitumumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced May 21, 2026, 7:19 PM EDT